A Study that will compare two modalities (SIB and SEQ IMRT),commonly being used for the treatment of Locally Advanced Oropharynx, Hypopharynx, Larynx cancer, in terms of acute toxicities, compliance of patients , Locoregional tumor control.
Not Applicable
- Conditions
- Health Condition 1: C13- Malignant neoplasm of hypopharynxHealth Condition 2: C32- Malignant neoplasm of larynxHealth Condition 3: C10- Malignant neoplasm of oropharynx
- Registration Number
- CTRI/2019/06/019493
- Lead Sponsor
- BHAGWAN MAHAVEER CANCER HOSPITAL AND RESEARCH CENTRE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
PATIENTS WITH LOCALLY ADVANCED OROPHARYNX,HYPOPHARYNX,LARYNX CANCER (STAGE III,IVA)
NORMAL RFT,LFT
KPS >70%
Exclusion Criteria
History of any previous irradiation.
History of any surgery for this malignancy
Recurrence of disease
Pregnancy
Collagen disorder
Metastatic disease
Hypersensitivity to contrast
Carcinoma Nasopharynx, Oral cavity.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparing incidence and severity of acute toxicity between study groups. <br/ ><br>Comparing compliance to the treatment between study groups. <br/ ><br>Comparing locoregional tumor control 3 months after completion of treatment between study groups. <br/ ><br>Timepoint: Comparing incidence and severity of acute toxicity between study groups. <br/ ><br>Comparing compliance to the treatment between study groups. <br/ ><br>Comparing locoregional tumor control 3 months after completion of treatment between study groups. <br/ ><br>
- Secondary Outcome Measures
Name Time Method Comparing incidence and severity of acute toxicity between study groups. <br/ ><br>Comparing compliance to the treatment between study groups. <br/ ><br>Comparing locoregional tumor control 3 months after completion of treatment between study groups.Timepoint: Comparing incidence and severity of acute toxicity between study groups. <br/ ><br>Comparing compliance to the treatment between study groups. <br/ ><br>Comparing locoregional tumor control 3 months after completion of treatment between study groups.